“Concept to Commercialization : Why the Current CRO Model May Be Failing Developers, Investors and Patients”
The first in a series of “Concept to Commercialization” presentations, this lecture will examine why the current CRO model may be failing developers, investors and patients. Does a new model CRO need introduction to the industry? Yes, according to pharmaceutical leader James Nolan, one that includes these four, key elements and available at the earliest stages of development:
• A reimbursement strategy
• Regulatory experts
• Pre-IND evaluation capabilities
• Patient access experts.
These added capabilities will allow CROs to separate themselves in a highly competitive industry. Mr. Nolan will also detail key issues complicating the concept to commercialization path for drug developers.